Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse
Other stock markets
 21:00:02 13/05/2024 BST 		5-day change 1st Jan Change
6.85 USD +15.51% Intraday chart for Annovis Bio, Inc. +27.09% -63.37%
05-10 Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-09 Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
GL
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
GL
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
AQ
Annovis Bio : Regulation FD Presentation - Form 8-K
PU
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
GL
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
GL
Annovis Bio : Material Agreement - Form 8-K
PU
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
AQ
Annovis Bio : Material Event - Form 8-K
PU
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
GL
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
AQ
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE
AQ
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
GL
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
GL
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
AQ
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
GL
Annovis Bio to Participate in the 139th Yale CEO Summit
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. News Annovis Bio, Inc.
  5. Press Releases